Jonathan Zalevsky - 22 Dec 2025 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Chief R&D Officer
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
22 Dec 2025
Net transactions value
$0
Form type
4
Filing time
23 Dec 2025, 18:01:49 UTC
Previous filing
25 Nov 2025
Next filing
22 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zalevsky Jonathan Chief R&D Officer C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO Mark A. Wilson, Attorney-in-Fact 23 Dec 2025 0001789857

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +6,250 +33% $0.000000 25,221 22 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +25,000 $0.000000 25,000 22 Dec 2025 Common Stock 25,000 $43.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substantially equal quarterly installments based on continued service.
F2 Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service.